Efficacy and safety of talquetamab in relapsed/refractory multiple myeloma and renal impairment: a quaternary cancer center cohort
Year: 2026
Type: article
Study design: Observational Study
Abstract: Patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment (RI) are considered a high-risk group frequently excluded from clinical trials. Patients with RI have a higher risk of disease progression or death compared to those without RI (relative risk (RR): 1.20 [1.003–1.431]) [ 1 ]. RI is a negative prognostic factor linked to early mortality, shorter overall survival (OS), and greater treatment-related toxicity. Only about 30% of trials clearly report the proportion of patients with RI, and eligibility criteria related to renal function are inconsistently applied, often leading to exclusion of these patients [ 2 , 3 ]. Talquetamab (Tal), a GPRC5D - targeting bispecific antibody (BsAb), received Food and Drug Administration (FDA) approval in August 2023 based on the findings from the MonumenTAL-1 clinical trial. Tal demonstrated high overall response rates (ORR) 69–74% and a manageable safety profile [ 4 ]. However, the absence of data in patients with RI means that efficacy and safety of Tal in this subgroup remain undefined.
Source: Blood Cancer Journal
Authors: Hossam M. Ali, Sandra Mazzoni, Utkarsh Goel, Jack Khouri, Faiz Anwer, Louis S. Williams, Diana Basali, Christy J. Samaras, Beth M. Faiman, Willem Van Heeckeren, Kimberly Hamilton, Joslyn Rudoni, Mikhaila Rice, Jonathan Kissam, Cynthia Scott, Saveta Mathur, Alexandra McDonald, Tara Roy, Julie Bevacqua, Marcelo C. Pasquini, Jason Valent, Shahzad Raza
Institution: Cleveland Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Funder: Cleveland Clinic
OpenAlex ID: W7159047508